Advertisement

 

 

TP53 Arg72Pro, mortality after cancer, and all-cause mortality in 105,200 individuals.

TP53 Arg72Pro, mortality after cancer, and all-cause mortality in 105,200 individuals.
Author Information (click to view)

Kodal JB, Vedel-Krogh S, Kobylecki CJ, Nordestgaard BG, Bojesen SE,


Kodal JB, Vedel-Krogh S, Kobylecki CJ, Nordestgaard BG, Bojesen SE, (click to view)

Kodal JB, Vedel-Krogh S, Kobylecki CJ, Nordestgaard BG, Bojesen SE,

Advertisement

Scientific reports 2017 03 237(1) 336 doi 10.1038/s41598-017-00427-x
Abstract

Rs1042522 (Arg72Pro) is a functional polymorphism of TP53. Pro72 has been associated with lower all-cause mortality and lower mortality after cancer. We hypothesized that TP53 Pro72 is associated with lower mortality after cancer, lower all-cause mortality, and with increased cancer incidence in the general population in a contemporary cohort. We genotyped 105,200 individuals aged 20-100 years from the Copenhagen General Population Study, recruited in 2003-2013, and followed them in Danish health registries. During follow-up 5,531 individuals died and 5,849 developed cancer. Hazard ratios for mortality after cancer were 1.03 (95% confidence interval:0.93-1.15) for Arg/Pro and 0.96 (95% CI:0.79-1.18) for Pro/Pro versus Arg/Arg. Hazard ratios for all-cause mortality were 0.99 (95% CI:0.93-1.04) for Arg/Pro and 1.09 (95% CI:0.98-1.21) for Pro/Pro versus Arg/Arg. Risk of cancer specific mortality, cardiovascular mortality, and respiratory mortality were not associated with Arg72Pro genotype overall; however, in exploratory subgroup analyses, genotype-associated risks of malignant melanoma and diabetes were altered. Considering multiple comparisons the latter findings may represent play of chance. The TP53 Arg72Pro genotype was not associated with mortality after cancer, all-cause mortality, or cancer incidence in the general population in a contemporary cohort. Our main conclusion is therefore a lack of reproducing an effect of TP53 Arg72Pro genotype on mortality.

Submit a Comment

Your email address will not be published. Required fields are marked *

one × 4 =

[ HIDE/SHOW ]